- Research works
- 38 ▲ 33% vs 2013–17
- Citations
- 1.6k 41.7 per fractional work
- Top-10% rate
- 27.4% record average 16.5%
- Open access
- 44% world 28%
Not ranked overall: Can-Fite BioPharma (Israel) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Chemistry, 5.4×. Every wedge is a field page.
Which keywords describe research at Can-Fite BioPharma (Israel)?
By fractional works in all years, weighted toward what it does more of than the world: Tumor Microenvironment, Inflammation, Neuroprotection, Immune Suppression, Therapeutic Targets, Adenosine Receptors, Purinergic Signalling and Cancer Therapy.
- Apoptosis
- Autoantibodies
- Synthesis
- Rheumatoid Arthritis
- NF-?B
- Biological Evaluation
- Anticancer
- Tumorigenesis
- Metastasis
- Drug Discovery
- Cancer
- Immunosuppression
- PET Imaging
- Cancer Therapy
- Adenosine Receptors
- Immune Suppression
- Inflammation
- Tumor Microenvironment
- Neuroprotection
- Therapeutic Targets
- Purinergic Signalling
- Angiogenesis
- Fibroblast Activation Protein
- Stromal Cells
- Cancer Progression
- Immunity
- Pim Oncogenes
- Transcriptional Regulation
- Regulation
- Cardiovascular Risk
- Neurodegeneration
- Signaling
- Antimicrobial
- Triazines
- Epigenetic Regulation
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 35 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 35 words, with their numbers
- Tumor Microenvironment15▲ 116×4 topics
- Inflammation14▲ 16×12 topics
- Neuroprotection10▲ 73×3 topics
- Immune Suppression10▲ 463×2 topics
- Therapeutic Targets10▲ 114×2 topics
- Adenosine Receptors10▲ 1044×1 topic
- Purinergic Signalling10▲ 1044×1 topic
- Cancer Therapy6▲ 27×6 topics
- Angiogenesis6▲ 39×5 topics
- PET Imaging6▲ 69×2 topics
- Fibroblast Activation Protein5▲ 265×1 topic
- Immunosuppression5▲ 117×1 topic
- Stromal Cells5▲ 152×2 topics
- Cancer3▲ 5.1×6 topics
- Cancer Progression2▲ 22×2 topics
- Drug Discovery2▲ 11×2 topics
- Immunity2▲ 13×3 topics
- Metastasis2▲ 13×2 topics
- Pim Oncogenes2▲ 234×1 topic
- Tumorigenesis2▲ 76×1 topic
- Transcriptional Regulation2▲ 16×2 topics
- Anticancer1▲ 20×2 topics
- Regulation1▲ 5.8×2 topics
- Biological Evaluation1▲ 26×2 topics
- Cardiovascular Risk1▲ 9.1×2 topics
- NF-?B1▲ 103×1 topic
- Neurodegeneration1▲ 9.9×2 topics
- Rheumatoid Arthritis1▲ 32×2 topics
- Signaling1▲ 28×1 topic
- Synthesis1▲ 5.6×2 topics
- Antimicrobial1▲ 11×1 topic
- Autoantibodies1▲ 13×2 topics
- Triazines1▲ 72×1 topic
- Apoptosis1▲ 7.0×3 topics
- Epigenetic Regulation1▲ 13×2 topics
Which research topics does Can-Fite BioPharma (Israel) publish most on?
By volume in 2022–2025: Peptidase Inhibition and Analysis, Adenosine and Purinergic Signaling, Cancer Mechanisms and Therapy and Cancer-related gene regulation.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Peptidase Inhibition and Analysis Oncology 1 works
- 2 Adenosine and Purinergic Signaling Physiology 1 works
- 3 Cancer Mechanisms and Therapy Pathology and Forensic Medicine 1 works
- 4 Cancer-related gene regulation Molecular Biology 0 works
- 5 Synthesis and biological activity Organic Chemistry 0 works
- 6 Urinary Bladder and Prostate Research Urology 0 works
- 7 Sexuality, Behavior, and Technology Clinical Psychology 0 works
- 8 Phytochemistry and biological activities of Ficus species Plant Science 0 works
- 9 Sexual function and dysfunction studies Psychiatry and Mental health 0 works
- 10 Bioactive natural compounds Molecular Biology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Can-Fite BioPharma (Israel)'s research output changed?
Output in 2018–2022 was 33% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Petah Tikva
- Rabin Medical Center
- Schneider Children's Medical Center
- New Technology (Israel)
- Geha Mental Health Center
- Teva Pharmaceuticals (Israel)
- Gemalto (Israel)
- Beit Rivka Geriatric Medical Center
- Gilat Satellite Networks (Israel)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.